C83.30
BillableDiffuse large B-cell lymphoma, unspecified site
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C83.30 an HCC code?
Yes. C83.30 maps to Lung and Other Severe Cancers under the CMS-HCC V28 risk adjustment model (and Lymphoma and Other Cancers under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C83.30
For C83.30to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C83.30 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C83.30 is the ICD-10-CM diagnosis code for diffuse large b-cell lymphoma, unspecified site. A type of cancer affecting large B-cells when the specific location of lymph node involvement is not documented or specified. C83.30 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).
Under the CMS-HCC V28 risk adjustment model, C83.30 maps to Lung and Other Severe Cancers (HCC 20) with a community, non-dual, aged base RAF weight of 1.136. Under the older CMS-HCC V24 model, C83.30 maps to Lymphoma and Other Cancers (HCC 10) with a community, non-dual, aged base RAF weight of 0.675. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
This is an unspecified site code; use only when documentation does not specify lymph node location. Because C83.30 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C83.30 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •This is an unspecified site code; use only when documentation does not specify lymph node location
- •Query provider if specific site information is available to assign a more specific code
Clinical Significance
Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma, accounting for approximately 30-40% of cases. It is an aggressive lymphoma that is potentially curable with chemoimmunotherapy (R-CHOP). The unspecified site code should only be used when documentation does not identify the involved lymph node region.
Documentation Requirements
- ✓Pathology confirmation with immunohistochemistry (CD20+, Ki-67 typically >40%)
- ✓Cell of origin determination (germinal center vs. activated B-cell subtype) per Hans algorithm
- ✓MYC, BCL2, BCL6 rearrangement status (double/triple hit assessment)
- ✓International Prognostic Index (IPI) score
- ✓Ann Arbor staging with bulk disease assessment
Commonly Confused Codes
- •C83.10 — Mantle cell lymphoma, unspecified; different subtype with different treatment and prognosis
- •C85.10 — Unspecified non-Hodgkin lymphoma; always use DLBCL-specific code when pathology confirms the subtype
- •C83.50 — Lymphoblastic lymphoma, unspecified; immature cell lymphoma with different treatment protocols
- •C83.80 — Other non-follicular lymphoma, unspecified; use only when DLBCL diagnosis cannot be confirmed